Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
July 15, 2019 06:00 ET
|
Capricor Therapeutics, Inc.
--Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspiratory Flow Reserve in the Randomized Double-Blind Placebo Controlled...
Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
January 24, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Neurology®, an international peer-reviewed journal, on Wednesday published the results of the HOPE-Duchenne clinical trial that evaluated the safety...
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 16:00 ET
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
February 22, 2018 13:23 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced the online publication in Stem Cell Reports of a new study by researchers at the Smidt Heart...